EN DE
Watch Andros Pharmaceuticals Co.,Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Andros Pharmaceuticals Co.,Ltd (6917) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Andros Pharmaceuticals Co.,Ltd stock TWD 17.54, price TWD 29.95, that is 41.4% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006917008

AP Andros Pharmaceuticals Co.,Ltd logo Thin data Nov 16, 2026

Andros Pharmaceuticals Co.,Ltd

6917 · TWO

Far too expensive (fair value 41% below the price) and weak company.

Get notified free when this changes
Mixed Growth (revenue 5y +11.2 %/yr in TWD) 
Mixed vs. peers (3/6) 
Fair value 17.54 TWD · Strongly overvalued 
Quality 32/100 
Negative free cash flow 
Narrow moat 23/100
Thin data 
Estimate
Watch Andros Pharmaceuticals Co.,Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

43.60 TWD 20.25 TWD Fair Value 17.54 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

12‑month range 20.25 TWD – 43.60 TWD · fair‑value band 13.15 TWD – 21.92 TWD · the 29.95 TWD price screens above the 17.54 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Andros Pharmaceuticals Co. in your weekly email

Every Wednesday you see whether Andros Pharmaceuticals Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies.

Show moreShow less

The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate.

Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain.

The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.

Stock analysis

Andros Pharmaceuticals Co.,Ltd (6917) currently trades at 29.95 TWD, while our estimate is 17.54 TWD, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 13.15 TWD (bear) to 21.92 TWD (bull), the price of 29.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Andros Pharmaceuticals Co.,Ltd reported revenue of 5.5M TWD in FY2025 versus 13.3M TWD in FY2021, a compound −19.7%/yr. Reported net income was −53.8M TWD in FY2025.

Key figures

Market cap 1.8B TWD (≈ $55.6M) Micro · EPS (TTM) −0.6300 TWD · Return on assets (EBIT) −18.1% (5-year average) · Free cash flow −46.4M TWD · Net cash 16.8M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 31% below its 52-week high and 48% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, 6917 screens richer than that median.

Fair Value

Bear 13.15 TWD Fair Value 17.54 TWD Bull 21.92 TWD
Price 29.95 TWD · Downside -41.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 5
Does it invest with discipline instead of growing at any price?
Low Volatility 5
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 48
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,298.7% (2020) → −1,363.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6917 screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Andros Pharmaceuticals Co.,Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −41.4% · Bottom 25%
Profitability
Return on assets −9.6% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.11× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 6917
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 6917
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 6917
argenx SE ARGX $950.95 $908.40 −4% vs 6917
CSL Limited CSL A$199.55 A$186.49 −7% vs 6917
Moderna, Inc MRNA $215.27 $135.64 −37% vs 6917
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 6917
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 6917
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 6917
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 6917

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Andros Pharmaceuticals Co.,Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Andros Pharmaceuticals Co.,Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6917

Frequently asked questions

Is Andros Pharmaceuticals Co.,Ltd (6917) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 17.54 TWD versus a price of 29.95 TWD, about 41% lower (overvalued).
What is the fair value of 6917?
Our estimate for Andros Pharmaceuticals Co.,Ltd is 17.54 TWD (as of Nov 16, 2026), built from audited fundamentals. The current price: 29.95 TWD.
What is the quality score of 6917?
Andros Pharmaceuticals Co.,Ltd has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Andros Pharmaceuticals Co.,Ltd (6917)?
Our calculated price target is the estimate of 17.54 TWD (as of Nov 16, 2026). Cautious scenario 13.15 TWD, optimistic scenario 21.92 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Andros Pharmaceuticals Co.,Ltd stock forecast for 2026?
Our estimate puts fair value at 17.54 TWD, about 41% lower versus a price of 29.95 TWD (overvalued). Cautious scenario 13.15 TWD, optimistic scenario 21.92 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Andros Pharmaceuticals Co.,Ltd (6917)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Andros Pharmaceuticals Co.,Ltd it is 17.54 TWD per share (as of Nov 16, 2026), against a price of 29.95 TWD.
Is Andros Pharmaceuticals Co.,Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 6917 trades above its calculated fair value: price 29.95 TWD, fair value 17.54 TWD, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6917?
No. The price is what the market pays today (29.95 TWD); the fair value is what the company's own numbers justify (17.54 TWD). For Andros Pharmaceuticals Co.,Ltd the two are 12.41 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Andros Pharmaceuticals Co.,Ltd worth?
The market values Andros Pharmaceuticals Co.,Ltd at about 1.8B TWD (market capitalisation, as of Nov 16, 2026). Per share that is 29.95 TWD; our models calculate a fair value of 17.54 TWD per share.
What do the bullish and bearish scenarios say about 6917?
Our models span a range for Andros Pharmaceuticals Co.,Ltd: cautious scenario 13.15 TWD, base 17.54 TWD, optimistic 21.92 TWD per share (as of Nov 16, 2026, price 29.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 6917 from its 52-week high?
Andros Pharmaceuticals Co.,Ltd trades at 29.95 TWD, about 31% below its 52-week high of 43.60 TWD and 48% above the low of 20.25 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 17.54 TWD is for.
Which stocks are comparable to Andros Pharmaceuticals Co.,Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Andros Pharmaceuticals Co.,Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 29.95 TWD, calculated fair value 17.54 TWD (−41%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Andros Pharmaceuticals Co.,Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Andros Pharmaceuticals Co.,Ltd (6917)?
The closing price on Nov 17, 2026 was 29.95 TWD. Our estimate is 17.54 TWD, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Andros Pharmaceuticals Co.,Ltd right now?
The price sits above even our optimistic bull case (21.92 TWD). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Andros Pharmaceuticals Co.,Ltd

How large is the market capitalisation of Andros Pharmaceuticals Co.,Ltd (6917)?
The market capitalisation of Andros Pharmaceuticals Co.,Ltd is 1.8B TWD (≈ $55.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Andros Pharmaceuticals Co.,Ltd (6917)?
Earnings per share at Andros Pharmaceuticals Co.,Ltd are −0.6300 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Andros Pharmaceuticals Co.,Ltd (6917)?
On an EBIT basis the return on assets of Andros Pharmaceuticals Co.,Ltd is −18.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Andros Pharmaceuticals Co.,Ltd (6917) generate?
The free cash flow of Andros Pharmaceuticals Co.,Ltd is −46.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Andros Pharmaceuticals Co.,Ltd (6917) hold?
Andros Pharmaceuticals Co.,Ltd holds more cash than debt, 16.8M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Andros Pharmaceuticals Co.,Ltd in the live analysis

One click puts Andros Pharmaceuticals Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.